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Abstract We recently identified a differentiation inhibiting fac- 
tor (I-factor) in mouse myeloid leukemia M1 cells as a murine 
homolog of nm23-H21nucleoside iphosphate kinase (NDPK)-B 
gene product. We examined the I-factor activities of several au- 
thentic nm231NDPK proteins, i.e recombinant rat NDPK a and 
t ,  recombinant mouse nm23-M1 and -M2, and recombinant 
human nm23-H1 and -H2 containing a mutant nm23-H2 his pro- 
tein lacing NDPK activity. Almost all these nm23/NDPK pro- 
teins showed I-factor activity. Moreover, to understand the active 
domain exhibiting I-factor activity of nm23-H2 protein lacking 
NDPK activity, we have investigated the I-factor activities of 
some truncated nm23-H2 proteins. The truncated nm23-H2 pro- 
tein containing N-terminal peptide 1-60 retained the I-factor 
activity. These results provide the first evidence for a function of 
nm23/NDPK as a differentiation inhibiting factor in leukemic 
cells, that is independent of its NDPK activity and dependent on 
the presence of N-terminal peptide. 
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1. Introduction 
Mouse myeloid leukemia M 1 cells, established from a spon- 
taneous myeloid leukemia in an SL mouse, can be induced to 
differentiate along the monocyte/macrophage pathway by var- 
ious inducers including dexamethasone, l~,25-dihydroxyvi- 
tamin D3, interleukin 6, and leukemia inhibitory factor/D-fac- 
tor (LIF/DF) [1,2]. The process of differentiation i duced in 
M 1 cells is similar to that of normal myeloid progenitor cells 
[3]. 
Activity to inhibit differentiation f M1 cells (l-factor activ- 
ity) was detected in a cell lysate and conditioned medium of the 
differentiation-resistant M 1 cells, but not in those of the paren- 
tal cells [4,5]. Moreover, the production of I-factor activity in 
these resistant M1 cells was well associated with their develop- 
ment of resistance to differentiation i ducers [6]. Recently, we 
purified one of the I-factors from conditioned medium of differ- 
entiation-resistant M 1 cells. The purified I-factor had a relative 
molecular mass of approximately 16,000-17,000 Da, and its 
amino acid sequence determined from cyanogen bromide frag- 
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Abbreviations: I-factor, a differentiation i hibitory factor of mouse 
myeloid leukemia M1 cells; NDPK, nucleoside diphosphate kinase; 
GST, glutathione S-transferase; LIF/DF, leukemia nhibitory factor/D- 
factor: PAGE, polyacrylamide g l electrophoresis. 
ments was identical with that of nm23 proteins, which are 
involved in tumor metastasis regulation and contain ucleoside 
diphosphate kinase (NDPK) enzyme activity (EC2.74.6) [7]. 
These results uggested that the nm23/NDPK protein might be 
the I-factor that suppresses differentiation f leukemic ells. 
nm23 was first identified as a gene expressed in lower 
amounts in highly metastatic rodent tumors than in poorly 
metastatic tumor cells [8]. Homologs of nm23 have been identi- 
fied in development of Drosophila s awd [9] and of Dictyoste- 
lium as gip 17 [10]. The deduced amino acid sequences of the 
products of these nm23 genes were found to share high homol- 
ogy with NDPK in a variety of species. The nm23 proteins, as 
well as their evolutionary homologs, have been demonstrated 
to have NDPK activity, although it has not been established 
that the enzyme activity mediates the biological effect of nm23 
[11-13]. In humans, NDPK A and B are identical to two 
isotypes of human m23 homologs, named nm23-H1 and -H2, 
respectively [12,14]. Two isotypes of nm23 homologs nm23-M 1 
and -M2, have also been found in mice [15]. Recently, another 
type of NDPK (NDPK-]~) in addition to NDPK-~, was identi- 
fied in rats [16]. It is, therefore, very likely that mammalian 
nm23/NDPKs have two isotypes with high mutual homology. 
Our previous results on amino acid sequence analysis howed 
that the purified I-factor is probably nm23-M2 [7,15], but it is 
unknown whether the 1-factor activity requires the NDPK ac- 
tivity of nm23 protein. 
In the present work, we examined (i) whether nm23/NDPK 
proteins have I-factor activity, and (ii) whether the NDPK 
activity is essential for the differentiation i hibitory activity of 
I-factor. 
2. Materials and methods 
2.1. Cells and cell culture 
M1 cells were cultured in Eagle's minimal essential medium (Nissui 
Seiyaku Co., Tokyo, Japan), supplemented with double the usual con- 
centrations ofamino acids and vitamins and 10% (v/v) heat-inactivated 
(56°C for 30 min) calf serum at 37°C under 5% CO2 in air. 
2.2. Assay of properties of differentiated cells 
Phagocytic activity was assayed using polystyrene latex particles, as 
reported previously [5]. Lysozyme activity in the cells was determined 
by the lysoplate method escribed previously [17]. Locomotive activity 
was assayed by the colonies with or without cell migration, as reported 
previously [1,5]. 
2.3. Assay of I-factor activity 
M1 cells (2 x 105/ml) were cultured for 2 days in the presence of 
dexamethasone (2 × 10-8M) with or without a test preparation. The 
ability of the preparation toinhibit he induction by dexamethasone f 
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phagocytic activity of cells was measured, and the I-factor activity was 
calculated as the percentage inhibition as reported previously [4,5]. 
2.4. nm23/NDPK proteins 
Rat recombinant NDPK proteins (c~ and fl) were produced in E. coli 
and purified and characterized as reported previously [18]. Murine and 
human recombinant m23 proteins (nm23-M1, -M2, -HI, and -H2) 
were produced as fusion proteins with 26 kDa glutathione S-transferase 
(GST) in E. coli and purified [15,19]. Using site-directed mutagenesis 
of cDNA encoding nm23-H2, we created the mutant nm23-H2 H~ pro- 
tein, where His ~8 was replaced by Cys because His H8 was the substrate 
for phosphoenzyme formation by ATP [20]. The mutant nm23-H2 His 
protein was produced as fusion protein with GST in E. coli. To create 
the truncated nm23-H2 proteins, plasmids were constructed toexpress 
the N-terminal peptidel-60 (nm23-H2-AX-CX), N-terminal peptidel- 
108 (nm23-H2-AX-DX), and C-terminal 61 152 (nm23-H2-EX-BX) of 
nm23-H2 proteins. Primers used for PCR of 5'-end (1-180)] region, 
5'-end (1-324) region, and 3'-end (181456) region of nm23-H2 gene 
coding regions were as follows: Sense primers: H2-AX, 5'-GGGGATC- 
CATGGCCAACCTGGAGCG-3'; H2-EX, 5'-GGGGATCCTTC- 
CCTGGGCTGGTGAA-3' (each primer contained a BamHI site). An- 
tisense primers: H2-CX, 5'-GGGAATTCAGAATGGTCGGTCT- 
TTCA-3'; H2-DX, 5'-GGGAATTCAGAAGTCCCCACGAATGG- 
3'; H2-BX, 5'-GGGAATTCATTCATAGACCCAGTCAT-3' (each 
primer contained a EcoRI site). All the nm23 GST fusion proteins were 
purified to homogeneity on SDS-PAGE by the procedure described 
previously ([15,19] Fig. 1A). Their NDPK activities were assayed by the 
phosphoenzyme formation of NDPK. Neither the mutant nm23 His pro- 
tein nor the truncated nm23-H2 proteins contained NDPK activity 
(Fig. 1B). All the proteins were dialyzed against phosphate buffered 
saline before the assay of the 1-factor activity. 
3. Results 
3.1. 1-factor activity of  recombinant nm23/NDPK proteins 
The I-factor activities of purified recombinant m23/NDPK 
proteins were examined. All the nm23/NDPK proteins used 
(human m23-H1 and -H2, mouse nm23-M1 and -M2, and rat 
NDPK-~ and -fl) inhibited the dexamethasone-induced differ- 
entiation of M1 cells (Fig. 2). Although nm23-H1, -H2, -M1, 
and -M2 were fusion proteins with GST, GST alone did not 
show any I-factor activity (Fig. 2A). Their I-factor activities 
were observed at very low concentrations of nm23/NDPK pro- 
teins, and at higher concentrations their I-factor activities de- 
creased. At their effective concentrations, nm23/NDPK pro- 
teins had no effect on proliferation of M1 cells. When differen- 
tiation was induced by dexamethasone, the presence of excess 
differentiation inducer counteracted the I-factor activity of 
nm23-M2 (data not shown). There were no marked differences 
in the I-factor activities of the isoforms of nm23/NDPK pro- 
teins (Fig. 2), although in some experiments nm23-M2 and -H2 
had higher I-factor activities than nm23-M1 and-H1. Next, we 
tested the inhibitory activity of nm23-M2 on dexamethasone- 
induced locomotive activity and lysozyme activity which were 
functional and biochemical markers of monocytic differentia- 
tion of M1 cells. The nm23-M2 protein also inhibited both 
locomotive and lysozyme activities (Table 1). The results indi- 
cate that all the purified recombinant nm23/NDPK proteins 
tested inhibited the differentiation of M 1 cells, and showed no 
species pecificity. 
3.2. 1-factor activity does not require NDPK activity 
To understand the active domain of nm23/NDPK protein for 
I-factor activity, we examined the 1-factor activities of some 
mutant nm23/NDPK proteins. One is the mutant nm23-H2 Hi~, 
which has Cys ~s instead of His jIB and does not have NDPK 
activity (Fig. 1B). This mutant cannot form a phosphoenzyme 
by ATP because His Hs, which is the substrate for phosphoen- 
zyme formation by ATP, is replaced by a Cys residue [20]. The 
mutant nm23-H2 His protein showed I-factor activity like wild 
type nm23-H2 protein (Fig. 3). These results suggest that 
NDPK activity is not required for the I-factor activity of nm23/ 
NDPK protein. Thus nm23/NDPK protein may have a new 
function, independent of its kinase activity. 
The other mutants used were truncated nm23-H2 proteins, 
which were N-terminal (1-60) peptide (nm23-H2-AX-CX), N- 
terminal (1-108) peptide (nm23-H2-AX-DX), and C-terminal 
(61 152) peptide (nm23-H2-EX-BX) of nm23-H2 protein. 
These truncated nm23-H2 proteins were also produced in 
E. coli in fusion form with GST and purified (Fig. 1). They were 
laking the NDPK activity (Fig. 1B). The N-terminal peptides 
(nm23-H2-AX-CX and nm23-H2-AX-DX) showed higher I- 
factor activity than the C-terminal peptide (nm23-H2-EX-BX) 
(Fig. 4). The N-terminal peptides inhibited not only the induc- 
tion by dexamethasone of phagocytic activity but also that of 
locomotive and lysozyme activities of M1 cells (data not 
shown). These results suggest hat at least the presence of the 
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Fig. 1. (A) SDS-PAGE analysis of purified nm23 H2 GST fusion proteins. The gel was stained with Coomassie blue dye. (B) NDPK activity of the 
purified nm23-H2 GST fusion proteins detected by the phosphoenzyme intermediate byautoradiography. The proteins (0.5 ¢tg) used were GST (lane 
1), nm23-H2 (lane 2), nm23-H2 his (lane 3), AX-CX (lane 4), AX-DX (lane 5) and EX-BX (lane 6). M, marker proteins. 
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Fig. 2. I-factor activities of various recombinant m23/NDPK proteins. The phagocytic activities of control cells in the presence of dexamethasone 
were (A) 52.8 _+ 1.9% (n = 4 S.D.), (B) 53.8 -+ 3,9% (n = 4, S.D.), and (C) 58.9 -+ 3.6 (n = 3, S.D.). 
N-terminal region of nm23-H2 protein is required for the l- 
factor activity. 
4. Discussion 
nm23 genes are implicated in tumor metastasis control 
through as yet unknown mechanisms. Depending on the cell 
type, metastatic spread has been correlated both with reduced 
nm23 expression [21-23], and with overexpression f nm23 [24]. 
nm23 genes are also involved in controlling normal cellular 
functions, including cell proliferation [25], differentiation [7,26], 
motility [27], and development, as indicated by high degree of 
homology between nm23 genes and the Drosophila awd gene 
vital to normal fruit fly development [9]. All nrn23/awd proteins 
contain NDPK enzyme activity [10-13], catalysing the synthesis 
of non-adenine-containing nucleoside triphosphates from nu- 
cleoside diphosphates. Additionally nm23/NDPK proteins 
have been described to interact with GTP-binding proteins 
[10,28], bind chromoglycate dye [29], autophospharylate s rine 
residue [30], and bind to DNA and stimulate transcription [31]. 
Of these functions of nm23/NDPK proteins, the antimetastatic 
potential of nm23 and the gene regulatory function (PuF) have 
been recently showed the independence with NDPK activity 
[30,32]. Moreover, MacDonald et al. presented thet a serine 
phosphorylation of nm23 correlated with suppression of 
tumor metastatic potential [30]. In the present study, we exam- 
ined the correlation between the NDPK activity and I-factor 
activity of nm23 proteins. Our results showed that the I-factor 
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Table 1 
Effect of nm23/NDP kinase on various markers of differentiation fM 1 
cells 
Marker of differentiation nm23-M2 Differentiation i ducer 
None Dex ~ 
Phagocytic activity (%) - 5.8 + 1.8 53.8 + 4.9 
+a 4.8 + 0.8 20.0 + 1.4 
Locomotive activity (%) - 0 47.5 + 15.3 
+b 0 10.4 + 5.3 
Lysozyme activity - 0 1.48 
(Units/mg protein) +b 0 0.87 
a0.1 ng/ml of nm23-M2; bl ng/ml of nm23-M2; ~2x 10 -8 M dexa- 
methasone; Values are means +_ S.D. (n = 4). 
10" 
O' 
0 0.001 0.1 10 
Human nm23 -H2 protein ( ng/ml  ) 
Fig. 3. I-factor activity of mutant nm23-H2 protein. The phagocytic 
activity of control cells in the presence of dexamethasone was 
57.3 + 9.7% (n --- 7, S.D). 
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Fig. 4. I-factor activity of truncated nm23-H2 proteins. The phagocytic 
activity of control cells in the presence of dexamethasone was 
56.5 + 4.3% (n = 4, S.D.). 
activity is not mediated by its kinase activity (Figs. 3 and 4). 
Namely, nm23/NDPK proteins may have another function that 
is independent of their NDPK activity. 
We are now trying to determine the active domain of nm23 
protein required for its I-factor activity. All previously identi- 
fied nm23/NDPKs, except hat in bacteria, share the tripeptide, 
Arg-Glyl°6-Asp, which is the RGD consensus sequence for the 
recognition of integrin family members. The I-factor activity in 
M 1 cells has been reported to be mainly localized in the mem- 
brane fraction [4]. Recently, the presence of nm23/NDPK pro- 
tein on the cell surface of some line cells has been reported [33], 
although the molecular mechanism of the surface xpression of 
nm23/NDPK protein is unknown. An intriguing possibility is 
that nm23/NDPK functions as a ligand for adhesive molecules 
of the integrin family. However, the truncated nm23-H2 pro- 
teins, lacking C-terminal peptide containing the RGD consen- 
sus sequence, xhibited I-factor activity (Fig. 4). On our prelim- 
inary experiment, he mutant nm23-H2 RGD protein, which has 
Ser 1°6 instead of Gly ~°6, also showed I-factor activity like wild 
type nm23-H2 protein (unpublished ata). These results sug- 
gest that the I-factor actitivity is not mediated by the RGD 
consensus equence of nm23 protein. The I-factor activity of 
nm23-H2 protein required the presence of N-terminal peptide 
(Fig. 4), containing leucine zipper motif, a serine phosphoryla- 
tion site (Ser"), and a mutation site (Leu 48) reported in aggres- 
sive childhood neuroblastomas. The mechanism by which I- 
factor inhibits induction of differentiation of M 1 cells is un- 
known, nm23/NDPK are mainly localized in the nucleus and 
cytosol with little in the plasma membrane [33]. We purified the 
I-factor from the culture medium of M1 cells, although nm23/ 
NDPK has no signal peptide for its secretion [5,7]. Recently, 
we found nm23 protein with NDPK activity in the culture 
supernatants of a variety of cell lines (T. Urano, K. Furukawa, 
and H. Shiku, manuscript in preparation), although the molec- 
ular mechanism of its secretion is unknown. 
On the basis of their nuclear localization and potential leuc- 
ine zipper motif, nm23-H2 and nm23-H1 were proposed to 
function as a transcription factors [14,21]. Postel et al. pre- 
sented evidence that nm23-H2 is a transcription factor (PuF) 
and that one of its targets is the c-myc gene [31]. Recently, they 
have reported that the NDPK activity of nm23-H2/PuF protein 
is not required for its function as a transcription factor [32]. It 
is interesting to investigate whether the c-myc transcription 
factor activity of nm23/H2 protein is required for its I-factor 
activity. Although no clear correlation has yet been established 
between overexpression of c-myc and tumor metastasis, the 
inverse relation between c-myc expression and cell differentia- 
tion is well documented. In M1 cells, the expression of c-myc, 
which is high during proliferation, is suppressed following in- 
duction of terminal differentiation and growth arrest [34]. 
Liebermann and Hoffman-Lieberman found that deregulated 
and continued expression of c-myc in M 1 cells inhibited termi- 
nal differentiation f the cells [35]. Our identification of I-factor 
in M1 cells as the murine homolog of nm23-H2 suggests that 
the possible interaction between c-myc and nm23 may occur 
during block of differentiation of leukemic ells. 
In conclusion, the present data provide the first evidence for 
nm23 function as a differentiation i hibitory factor in leukemic 
cells independent of its NDPK activity and dependent of the 
presence of its N-terminal region of nm23/I-factor protein. 
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